Seasonal Allergy Market by Form, Prescription, Route of Administration, Treatment, Distribution Channel & Region | Forecast 2023 to 2033

<p>The global <strong>seasonal allergy market </strong>enjoys a valuation of US$ 1.15 Billion in 2022, and it is further projected to expand at a CAGR of 7.8% over the forecasted years. According to a recent study by Future Market Insights, tablets/capsules by form leading the market with a share of about 37.1% in the year 2022, within the global market.</p><table><tbody><tr><th scope='row'>Data Points</th><td>Market Insights</td></tr><tr><th scope='row'>Market Value 2022</th><td>US$ 1.15 Billion</td></tr><tr><th scope='row'>Market Value 2033</th><td>US$ 2.58 Billion</td></tr><tr><th scope='row'>CAGR 2023 to 2033</th><td>7.8%</td></tr><tr><th scope='row'>Market Share of Top 5 Countries</th><td>62.1%</td></tr><tr><th scope='row'>Key Market Players</th><td>Merck KGaA, Johnson &amp; Johnson, Allergopharma, Sanofi SA, McNeil Consumer Healthcare, Genentech Inc., GlaxoSmithKline PLC, Leti Pharma, Alerpharma S.A, Allergan, Inc., Meda Pharmaceuticals, Inc, Novartis International AG, Bausch Health Companies Inc., Allergopharma, ALK Abello, Stallergenes, Greer, Allergy Therapeutics, Aimmune Therapeutics, Biomay AG, HAL Allergy Group, Bayer, AstraZeneca</td></tr></tbody></table><p>Report Scope as per Seasonal Allergy Industry Analysis</p><table><tbody><tr><th scope='row'>Attribute</th><td>Details</td></tr><tr><th scope='row'>Forecast Period</th><td>2018 to 2022</td></tr><tr><th scope='row'>Historical Data Available for</th><td>2023 to 2033</td></tr><tr><th scope='row'>Market Analysis</th><td>US$ Million for Value</td></tr><tr><th scope='row'>Key Regions Covered</th><td>North America, Latin America, Europe, South Asia, East Asia, Oceania, and the Middle East &amp; Africa</td></tr><tr><th scope='row'>Key Countries Covered</th><td>The USA, Canada, Brazil, Mexico, Argentina, The United kingdom, Germany, Italy, Russia, Spain, France, Benelux, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, T&uuml;rkiye, GCC Countries, North Africa and South Africa</td></tr><tr><th scope='row'>Key Market Segments Covered</th><td>Form, Prescription Type, Route of Administration, Treatment, Distribution Channel</td></tr><tr><th scope='row'>Key Companies Profiled</th><td><ul><li>Merck KGaA</li><li>Johnson &amp; Johnson</li><li>Allergopharma</li><li>Sanofi SA</li><li>McNeil Consumer Healthcare,</li><li>Genentech Inc.</li><li>GlaxoSmithKline PLC</li><li>Leti Pharma,</li><li>Alerpharma S.A</li><li>Allergan, Inc.</li><li>Meda Pharmaceuticals, Inc</li><li>Novartis International AG</li><li>Bausch Health Companies Inc.</li><li>Allergopharma</li><li>ALK Abello</li><li>Stallergenes Greer</li><li>Allergy Therapeutics</li><li>Aimmune Therapeutics</li><li>Biomay AG</li><li>HAL Allergy Group</li><li>Bayer</li><li>AstraZeneca</li></ul></td></tr><tr><th scope='row'>Pricing</th><td>Available upon Request</td></tr></tbody></table>

<p>全球季节性过敏市场在2022年实现了115亿美元的估值，预计在未来预测期内将以7.8%的复合年增长率持续扩张。根据未来市场洞察力公司的一项最新研究，以片剂/胶囊剂型为主的产品在2022年占据了市场约37.1%的份额，在全球市场中处于领先地位。</p><table><tbody><tr><th scope='row'>数据点</th><td>市场洞察</td></tr><tr><th scope='row'>2022年市场价值</th><td>11.5亿美元</td></tr><tr><th scope='row'>2033年市场价值</th><td>25.8亿美元</td></tr><tr><th scope='row'>2023至2033年复合年增长率</th><td>7.8%</td></tr><tr><th scope='row'>前五大国家市场份额</th><td>62.1%</td></tr><tr><th scope='row'>主要市场参与者</th><td>默克集团、强生、Allergopharma、赛诺菲SA、McNeil消费者保健、基因泰克公司、葛兰素史克PLC、Leti药业、Alerpharma S.A、艾尔利安、Meda制药公司、诺华国际AG、百时美施贵宝公司、Bausch Health公司、Allergopharma、ALK Abello、Stallergenes Greer、过敏治疗、Aimmune治疗学、Biomay AG、HAL过敏集团、拜耳、阿斯利康</td></tr></tbody></table><p>根据季节性过敏行业分析报告范围</p><table><tbody><tr><th scope='row'>属性</th><td>详细信息</td></tr><tr><th scope='row'>预测期</th><td>2018至2022年</td></tr><tr><th scope='row'>可提供历史数据</th><td>2023至2033年</td></tr><tr><th scope='row'>市场分析</th><td>以百万美元为单位的价值</td></tr><tr><th scope='row'>主要覆盖区域</th><td>北美、拉丁美洲、欧洲、南亚、东亚、大洋洲和中东及非洲</td></tr><tr><th scope='row'>主要覆盖国家</th><td>美国、加拿大、巴西、墨西哥、阿根廷、英国、德国、意大利、俄罗斯、西班牙、法国、比荷卢、印度、泰国、印度尼西亚、马来西亚、日本、中国、韩国、澳大利亚、新西兰、土耳其、GCC国家、北非和南非</td></tr><tr><th scope='row'>主要市场细分</th><td>剂型、处方类型、给药途径、治疗、分销渠道</td></tr><tr><th scope='row'>主要公司简介</th><td><ul><li>默克集团</li><li>强生</li><li>Allergopharma</li><li>赛诺菲SA</li><li>McNeil消费者保健</li><li>基因泰克公司</li><li>葛兰素史克PLC</li><li>Leti药业</li><li>Alerpharma S.A</li><li>艾尔利安</li><li>Meda制药公司</li><li>诺华国际AG</li><li>百时美施贵宝公司</li><li>Bausch Health公司</li><li>Allergopharma</li><li>ALK Abello</li><li>Stallergenes Greer</li><li>过敏治疗</li><li>Aimmune治疗学</li><li>Biomay AG</li><li>HAL过敏集团</li><li>拜耳</li><li>阿斯利康</li></ul></td></tr><tr><th scope='row'>定价</th><td>根据要求提供</td></tr></tbody></table>